| Autor: |
Fischer S; Kantonsspital St Gallen, Klinik für Medizinische Onkologie und Hämatologie, St Gallen, Switzerland., Götze TO; Krankenhaus Nordwest GmbH, Institut für Klinisch-Onkologische Forschung, Frankfurt, Germany., Omlin A; Kantonsspital St Gallen, Klinik für Medizinische Onkologie und Hämatologie, St Gallen, Switzerland., Baird RD; Cancer Research UK Cambridge Centre, Cambridge, United Kingdom., Dawson KM; Molecular Partners AG, Schlieren, Switzerland., Zitt C; Molecular Partners AG, Schlieren, Switzerland., Arany Z; Molecular Partners AG, Schlieren, Switzerland., Tresch G; Molecular Partners AG, Schlieren, Switzerland., Fiedler U; Molecular Partners AG, Schlieren, Switzerland.; NBE-Therapeutics AG/Boehringer Ingelheim, Basel, Switzerland., Jeger S; Molecular Partners AG, Schlieren, Switzerland., Fung S; Fung Consulting, Eching, Germany., Legenne P; Molecular Partners AG, Schlieren, Switzerland., Leupin N; Molecular Partners AG, Schlieren, Switzerland., Schneeweiss A; National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany., Fremd C; National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany. |
